Palladia® — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Palladia®

Active ingredient

Toceranib Phosphate

Application type

NADA

Sponsor

Zoetis Inc.

Applications on record

1

First published

May 17, 2021

Adverse event reports

Source: openFDA VeDDRA

1,262

Reports mentioning this ingredient

September 10, 2008 – March 24, 2026

296

Classified serious

per reporter assessment

171

Lack of expected efficacy

resistance signal

11

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “TOCERANIB PHOSPHATE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Diarrhoea	214
Vomiting	195
Anorexia	168
Anaemia NOS	111
Death by euthanasia	103
Neutropenia	99
Lack of efficacy - NOS	99
Lameness	91
Weight loss	87
Lethargy (see also Central nervous system depression in 'Neurological')	84
Elevated serum alkaline phosphatase (SAP)	81
Leucopenia NOS	79
Elevated alanine aminotransferase (ALT)	71
Depression	62
Death	62
Decreased appetite	58
Other abnormal test result NOS	45
Elevated blood urea nitrogen (BUN)	44
Loose stool	43
Thrombocytopenia	43

Species affected

Source: openFDA VeDDRA

Dog 1,058 Cat 99 Human 27 Other Rodents 1 Rabbit 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient